(Q33906531)

29 July 2017

1 reference

title

Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation (English)

1 reference

29 July 2017

Essayan DM

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

29 July 2017

published in

Biochemical Pharmacology

1 reference

29 July 2017

volume

57

1 reference

29 July 2017

issue

9

1 reference

29 July 2017

page(s)

965-973

1 reference

On the medical history of xanthines and other remedies for asthma: a tribute to HH Salter

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Modulation of inflammation and immunity by cyclic AMP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Chromosome localizations of genes for five cAMP-specific phosphodiesterases in man and mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Multiple splice variants of phosphodiesterase PDE4C cloned from human lung and testis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Zinc dependent activation of cAMP-specific phosphodiesterase (PDE4A)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by 1H NMR and identification of the membrane association domain using chimeric constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Recombinant expression of a type IV, cAMP-specific phosphodiesterase: characterization and structure-function studies of deletion mutants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Tailoring cAMP-signalling responses through isoform multiplicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

The genetic subtypes of cAMP-dependent protein kinase--functionally different or redundant?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Identification of two splice variant forms of type-IVB cyclic AMP phosphodiesterase, DPD (rPDE-IVB1) and PDE-4 (rPDE-IVB2) in brain: selective localization in membrane and cytosolic compartments and differential expression in various brain regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Alternative splicing of the type-IVA cyclic AMP phosphodiesterase gene provides isoform variants with distinct N-terminal domains fused to a common, soluble catalytic unit: 'designer' changes in Vmax, stability and membrane association.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Phosphorylation of a cAMP-specific phosphodiesterase (HSPDE4B2B) by mitogen-activated protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Regulation of cyclic AMP phosphodiesterase activity by particulate protein tyrosine kinase and phosphotyrosine phosphatase activities sensitive to sodium orthovanadate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of phosphodiesterase inhibitors on human lung mast cell and basophil function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Pharmacologic control of histamine release from human basophils induced by platelet-activating factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic nucleotide phosphodiesterases in the human lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic AMP phosphodiesterases in human lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgE production stimulated by IL-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effect of Cyclic AMP-Elevating Agents on Human Spontaneous IgE Synthesis in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic nucleotide phosphodiesterases from purified human CD4+ and CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Interactions between cAMP- and cGMP-dependent protein kinase inhibitors and phosphodiesterase IV inhibitors on arachidonate release from human monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Interactions of formylmethionyl-leucyl-phenylalanine, adenosine, and phosphodiesterase inhibitors in human monocytes. Effects on superoxide release, inositol phosphates and cAMP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

The specific type IV phosphodiesterase inhibitor rolipram differentially regulates the proinflammatory mediators TNF-alpha and nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Suppression of tumor necrosis factor-α production by interleukin-10 is enhanced by cAMP-elevating agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Anti-inflammatory activities of cAMP-elevating agents: enhancement of IL-10 synthesis and concurrent suppression of TNF production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Tumour necrosis factor alpha-induced oxidative burst in neutrophils adherent to fibronectin: effects of cyclic AMP-elevating agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic AMP-elevating agents down-regulate the oxidative burst induced by granulocyte-macrophage colony-stimulating factor (GM-CSF) in adherent neutrophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Inhibition of human neutrophil degranulation by forskolin in the presence of phosphodiesterase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effect of xanthine derivatives on chemotactic polypeptide-induced superoxide and enzyme release from human polymorphonuclear leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Suppression of mesangial proliferative glomerulonephritis development in rats by inhibitors of cAMP phosphodiesterase isozymes types III and IV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Rolipram, a phosphodiesterase-4-selective inhibitor, promotes the survival of cultured rat dopaminergic neurons.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

cAMP-specific phosphodiesterase inhibitor, rolipram, reduces eosinophil infiltration evoked by leukotrienes or by histamine in guinea pig conjunctiva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of rolipram on responses to acute and chronic antigen exposure in monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Oral milrinone in severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Theophylline and mucociliary clearance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Theophylline does not increase ventilatory responses to hypercapnia or hypoxia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

The effect of zaprinast (M&B 22,948, an orally absorbed mast cell stabilizer) on exercise-induced asthma in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2898%2900331-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-2952(98)00331-1

1 reference

29 July 2017

1 reference